CHINESE regulators have approved Pfizer Inc.’s blockbuster vaccine Prevenar 13, the U.S. drugmaker said yesterday, a breakthrough for the firm after it was forced to shut its vaccine business in China last year.

    Prevenar, one of Pfizer’s top selling products, is used primarily for infants to help prevent pneumococcal disease, a bacterial infection that can lead to illnesses such as pneumonia, meningitis and sepsis.

    Pfizer shuttered its China vaccines business after a license for an earlier version of Prevenar was not renewed in 2015.

    Foreign drugmakers face growing difficulties obtaining approvals for medicines in China, the world’s No. 2 drug market.

    The U.S. firm said it had received approval from the China Food and Drug Administration (CFDA) to market Prevenar 13 to infants and children aged between six weeks to 15 months.

    “We applaud the efforts of the CFDA and other relevant government agencies to bring new medicines and vaccines to the Chinese health care system,” Wu Xiaobin, president of Pfizer China, said.

    The firm aims to make the vaccine available in China within the earliest possible timeframe, but there was no set date, said Pfizer spokeswoman Trupti Wagh.

    (SD-Agencies)